<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583710</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0948</org_study_id>
    <secondary_id>NCI-2018-01101</secondary_id>
    <secondary_id>2017-0948</secondary_id>
    <nct_id>NCT03583710</nct_id>
  </id_info>
  <brief_title>Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2)</brief_title>
  <official_title>Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amercian Australian Asian Adrenal Alliance (A5)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network for the Study of Adrenal Tumors (ENS@T)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial studies how well mitotane alone works compared to mitotane with
      cisplatin and etoposide when given after surgery in treating participants with adrenocortical
      cancer that has a high risk of coming back. Cortisol can cause the growth of adrenocortical
      tumor cells. Antihormone therapy, such as mitotane, may lessen the amount of cortisol made by
      the body. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways
      to stop the growth of tumor cells, either by killing the cells, by stopping them from
      dividing, or by stopping them from spreading. It is not yet known whether mitotane alone or
      mitotane with cisplatin and etoposide after surgery works better in treating participants
      with adrenocortical carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the effect of adjuvant mitotane treatment alone (arm A) with that of adjuvant
      mitotane combined with four 21-day cycles of etoposide/cisplatin (arm B) on recurrence-free
      survival (RFS) in patients with high-risk adrenocortical carcinoma (ACC) after initial
      surgical resection.

      SECONDARY OBJECTIVES:

      I. Assess overall survival (OS), defined as the time interval between the date of
      randomization and the date of death from any cause.

      II. Assess the effect of serum mitotane levels, disease stage, and surgical resection margins
      on clinical outcomes.

      III. Assess the effect of early start (1-6 weeks from surgery) vs. late start (&gt; 6 weeks from
      surgery) of adjuvant therapy on clinical outcomes.

      IV. Assess serious adverse events (grade 3 and above) according to the National Cancer
      Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.03).

      V. Measure quality of life at baseline, 6 weeks, 6 months after the initiation of adjuvant
      therapy, and at the end of study participation (recurrence or completing study treatments)
      using a validated quality of life questionnaire (European Organization for Research and
      Treatment of Cancer [EORTC] QLQ-C30).

      EXPLORATORY OBJECTIVES:

      I. Perform molecular profiling on available tissue specimens obtained at the time of initial
      surgical resection (formalin-fixed paraffin-embedded or frozen tissues) to identify genomic
      alterations in primary tumors that are associated with the clinical end points. II. Evaluate
      markers to detect ACC recurrence or predict response to therapy (including steroid hormones
      and precursors, circulating tumor cells, and micro ribonucleic acid [microRNA]).

      OUTLINE: Participants are randomized to 1 of 2 arms.

      ARM A: Participants receive mitotane orally (PO) daily on days 1-21. Courses repeat every 21
      days for 2 years in the absence of disease progression or unacceptable toxicity.

      ARM B: Participants receive mitotane as in Arm A. Participants also receive cisplatin
      intravenously (IV) over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment
      repeats every 21 days for up to 4 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, participants are followed up every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">January 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>From the time of randomization up to 2 years</time_frame>
    <description>Starting from the date of randomization until documentation of radiological evidence of local recurrence, radiological evidence of distant recurrence, or death from any cause (whichever occurs first), RFS will be compared using the log-rank test between the two arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local recurrence of adrenocortical carcinoma (ACC)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distant recurrence of ACC</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the time of randomization up to 2 years</time_frame>
    <description>Overall survival will be compared using the log-rank test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>ENSAT Stage I Adrenal Cortex Carcinoma</condition>
  <condition>ENSAT Stage II Adrenal Cortex Carcinoma</condition>
  <condition>ENSAT Stage III Adrenal Cortex Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (mitotane)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive mitotane PO daily on days 1-21. Courses repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (mitotane, etoposide, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive mitotane as in Arm A. Participants also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (mitotane, etoposide, cisplatin)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloramine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (mitotane, etoposide, cisplatin)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitotane</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (mitotane)</arm_group_label>
    <arm_group_label>Arm B (mitotane, etoposide, cisplatin)</arm_group_label>
    <other_name>(o,p)-DDD</other_name>
    <other_name>1, 1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane</other_name>
    <other_name>1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene</other_name>
    <other_name>2, 2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane</other_name>
    <other_name>2, 4'-Dichlorodiphenyldichloroethane</other_name>
    <other_name>CB 313</other_name>
    <other_name>CB-313</other_name>
    <other_name>Chloditan</other_name>
    <other_name>Chlodithane</other_name>
    <other_name>DDD</other_name>
    <other_name>Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-</other_name>
    <other_name>Khloditan</other_name>
    <other_name>Lisodren</other_name>
    <other_name>Lysodren</other_name>
    <other_name>Mytotan</other_name>
    <other_name>o,p' - DDD</other_name>
    <other_name>o,p'-DDD</other_name>
    <other_name>Ortho,para-DDD</other_name>
    <other_name>WR-13045</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (mitotane)</arm_group_label>
    <arm_group_label>Arm B (mitotane, etoposide, cisplatin)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a histologically confirmed diagnosis of ACC (Weiss score of &gt;= 3).
             (LinWeiss-Bisceglia system will be used for oncocytic ACC).

          -  Have a high risk of relapse defined as: Stage I-III ACC (according to the European
             Network for the Study of Adrenal Tumors [ENSAT] classification) within 90 days of
             surgical resection of primary tumor with curative intent with either microscopically
             complete resection (R0, defined as no evidence of microscopic residual disease
             according to surgical reports, histopathology, and perioperative imaging),
             microscopically positive margins (R1), or undetermined margins (RX, based on surgical
             or pathological reports without unequivocal evidence of metastasis in the
             perioperative imaging). Each participating center will determine the pathological
             stages and resection margins AND Ki67 &gt; 10% (to be determined by an experienced
             pathologist in each participating center and preferably via quantitative imaging
             analysis).

          -  Have perioperative imaging (computed tomography [CT] with contrast, magnetic resonance
             imaging [MRI] of the chest/abdomen/pelvis, or fluorodeoxyglucose positron emission
             tomography [FDG-PET] CT) without unequivocal evidence of disease within 4 weeks before
             randomization. Patients with indeterminate non-specific nodules (&lt; 1 cm for soft
             tissue lesions and &lt; 1.5 cm in the short dimension for lymph nodes) will be permitted
             to participate in this study.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  Be able to comply with the protocol procedures.

          -  Provide written informed consent.

        Exclusion Criteria:

          -  The time between primary surgery and randomization &gt; 90 days.

          -  They have undergone repeated surgery for recurrence of disease.

          -  They have a history of recent or active prior malignancy, except for cured
             non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in
             situ, or other treated malignancies where there has been no evidence of disease for at
             least 2 years.

          -  They have renal insufficiency (estimated glomerular filtration rate [GFR] &lt; 50
             mL/min/1.73 m^2). GFRs will be calculated according to the validated formula
             (Modification of Diet in Renal Disease [MDRD]).

          -  They have significant liver insufficiency (serum bilirubin &gt; 2 times the upper normal
             range)

          -  They have significant liver insufficiency (serum alanine aminotransferase [ALT] or
             aspartate aminotransferase [AST] &gt; 3 times the upper normal range)

          -  Impaired bone marrow reserve (neutrophils &lt; 1000/mm^3)

          -  Impaired bone marrow reserve (platelets &lt; 100,000/mm^3)

          -  Pregnancy or breast feeding.

          -  They have known congestive heart failure (ejection fraction &lt; 45%). In patients with a
             history of cardiac disease, a baseline two-dimensional echocardiogram is needed as
             standard of care to document ejection fraction. In patients without prior cardiac
             disease, a baseline electrocardiogram (EKG) is sufficient if there is no evidence of
             acute ischemic changes or prior evidence of myocardial infarction. If EKG results are
             abnormal (ischemic changes, significant arrhythmia, or suggestion of prior myocardial
             infarction), a two-dimensional echocardiogram will be obtained to assess ejection
             fraction.

          -  They have preexisting grade 2 peripheral neuropathy.

          -  They underwent previous or current treatment with mitotane or other antineoplastic
             drugs for ACC.

          -  They underwent previous radiotherapy for ACC.

          -  They have any other severe acute or chronic medical or psychiatric condition or
             laboratory abnormality that would impart, in the judgment of the investigator, excess
             risk associated with study participation or study drug administration or that, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mouhammed Habra</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Terzolo</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Luigi Gonzaga Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rossella Libé</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cochin Hospital -Paris -France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mouhammed Habra</last_name>
    <phone>713-792-2841</phone>
    <email>mahabra@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mouhammed A. Habra</last_name>
      <phone>713-792-2841</phone>
      <email>mahabra@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Mouhammed A. Habra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenal Cortex Neoplasms</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Mitotane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

